Global Ischemia Therapeutic Development Pipeline Review, H2 2015 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/b7pqf3/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Ischemia Overview
  3. Therapeutics Development
  4. Pipeline Products for Ischemia - Overview
  5. Pipeline Products for Ischemia - Comparative Analysis
  6. Ischemia - Therapeutics under Development by Companies
  7. Ischemia - Therapeutics under Investigation by Universities/Institutes
  8. Ischemia - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Ischemia - Products under Development by Companies
  13. Ischemia - Products under Investigation by Universities/Institutes
  14. Ischemia - Companies Involved in Therapeutics Development
  • Alize Pharma SAS
  • Amyndas Pharmaceuticals LLC
  • AnGes MG, Inc.
  • Apceth GmbH & Co. KG
  • Athersys, Inc.
  • Baxalta Incorporated
  • Caladrius Biosciences, Inc.
  • Cellmid Limited
  • CoDa Therapeutics, Inc.
  • CohBar, Inc.
  • Cynata Therapeutics Limited
  • DNAVEC Corporation
  • GlaxoSmithKline Plc
  • Hemostemix Ltd
  • IntelliCell BioSciences Inc.
  • Juventas Therapeutics, Inc.
  • Kasiak Research Private Limited
  • Lixte Biotechnology Holdings, Inc.
  • Mesoblast Limited
  • Miltenyi Biotec GmbH
  • Mirrx Therapeutics A/S
  • Multi Gene Vascular Systems Ltd
  • NoNO, Inc.
  • Nyken BV
  • Pathfinder Cell Therapy, Inc.
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • Protagenic Therapeutics Inc.
  • ReNeuron Group Plc
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Stempeutics Research Private Limited
  • Targazyme, Inc.
  • Taxus Cardium Pharmaceuticals Group Inc.
  • TikoMed AB
  • U.S. Stem Cell, Inc.

For more information visit http://www.researchandmarkets.com/research/b7pqf3/ischemia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular